The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
第一作者:
Lu,Chen
第一单位:
Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
作者:
主题词
动物(Animals);抗代谢药, 抗肿瘤(Antimetabolites, Antineoplastic);抗肿瘤药(Antineoplastic Agents);癌, 肾细胞(Carcinoma, Renal Cell);DNA甲基化(DNA Methylation);抗药性, 肿瘤(Drug Resistance, Neoplasm);表观基因组学(Epigenomics);平衡核苷转移子1(Equilibrative Nucleoside Transporter 1);血红蛋白类(Hemoglobins);组蛋白脱乙酰基酶类(Histone Deacetylases);组蛋白类(Histones);人类(Humans);缺氧诱导因子1, α亚基(Hypoxia-Inducible Factor 1, alpha Subunit);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);纳米粒子(Nanoparticles);启动区, 遗传(Promoter Regions, Genetic);RNA, 信使(RNA, Messenger);阻遏蛋白质类(Repressor Proteins);增量调节(Up-Regulation)
DOI
10.7150/thno.39944
PMID
32206108
发布时间
2024-03-28
- 浏览0

Theranostics
3562-3578页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文